BioCentury | Aug 26, 2020
Product Development

Sizing up Ovid’s soticlestat among Dravet therapies

...Tuesday: Ovid $0.04 to $6.34; GW $3.02 to $103.25; and Zogenix $0.13 to $22.80.TARGETSCYP46A1 (CH24H) – Cytochrome P450...
BioCentury | May 13, 2020
Product Development

Arvinas unveils first efficacy signal for targeted protein degradation, points to opportunity in resistant cancers

...for ARV-471 this half. Targets AR-V7 - Androgen receptor splice variant 7 CYP17 (CYP17A) - Cytochrome P450...
BioCentury | Jan 16, 2020
Company News

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

...cancer 2 early onset; CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4; CYP11B1 - Cytochrome P450...
...1 early onset (BRCA1) Breast cancer 2 early onset (BRCA2) Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152) Cytochrome P450...
BioCentury | Nov 11, 2019
Emerging Company Profile

Mycovia tackling chronic infections with antifungal pipeline

...Capital Management LLC. Like fluconazole and other azole drugs, VT-1161 works by targeting the fungal P450...
...is that VT-1161 is selective for fungal CYP51, whereas marketed antifungals also bind to mammalian P450...
...said the promiscuity of marketed azoles comes from binding to an element that’s shared among P450...
BioCentury | Jun 19, 2019
Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

...receive undisclosed development funding, royalties and regulatory and sales milestones. The oral inhibitor of fungal cytochrome P450...
...Bacteria Biopharmaceutical Accelerator Jiangsu Hengrui Medicine Co. Ltd. Kowa Co. Ltd. Merck & Co. Inc. Sino Biopharmaceutical Ltd. TrakCel Ltd. Fungal cytochrome P450...
BioCentury | Jun 13, 2019
Translation in Brief

Syntrix analgesic overcomes tramadol’s dependence on CYP2D6

...other opioids, and to carry less potential for abuse. But because it is metabolized by cytochrome P450...
...but has raised nearly $90 million from NIH grants and licenses. Sandi Wong, Staff Writer Omnitram Syntrix Biosystems Inc. Cytochrome P450...
BioCentury | May 20, 2019
Distillery Techniques

RB1 alterations predict survival in mCRPC patients treated with Zytiga or Xtandi

...Xtandi for prostate cancer. BTG plc, AstraZeneca plc and Johnson & Johnson market Zytiga, a cytochrome P450...
BioCentury | May 17, 2019
Tools & Techniques

Leaning on exosomes, model-informed drug development gets closer to tailoring doses to each patient

...The available tests use genetic variants of proteins that regulate drug response, such as the cytochrome P450...
...CYP1A2 - Cytochrome P450 family 1 subfamily A polypeptide 2 CYP2D6 - Cytochrome P450 2D6 CYP3A4 - Cytochrome P450...
BioCentury | Mar 28, 2019
Translation in Brief

Tuning metabolism in liver organoids

...AAT (A1AT; SERPINA1) - α-1 antitrypsin; ASGR1 (ASPGR; CLEC4H1) - Asialoglycoprotein receptor 1; CYP3A4 - Cytochrome P450...
BioCentury | Mar 25, 2019
Clinical News

Avanir's AVP-786 meets in Phase III for Alzheimer's agitation

...antagonist. Both AVP-786 and AXS-05 have Fast Track designation in the U.S. Targets: CYP2D6 - Cytochrome P450...
Items per page:
1 - 10 of 691